Intra-Cellular Therapies, Inc. (ITCI)

業務介紹

Intra-Cellular Therapies, Inc.（Intra-Cellular Therapies公司）是一家生物製藥公司，致力於開發針對中樞神經系統內部細胞信號機制的新型藥物，用於治療神經精神疾病和神經病理學疾病。該公司在美國提供CAPLYTA用於成年人的精神分裂症治療。該公司還致力於開發lumateperone，該藥正在進行III期臨床試驗，用於治療躁鬱性抑鬱症，以及治療自閉症譜系障礙；同時也在開發其他神經精神疾病指標，如與神經精神疾病和神經病理學疾病相關的睡眠障礙。此外，該公司還在開發Lenrispodun（ITI-214）用於治療帕金森病和心力衰竭；ITI-1284-ODT-SL用於治療神經精神疾病和痴呆症的行為障礙；以及ITI-333用於治療物質濫用障礙、疼痛和與抑鬱症和焦慮症等精神共病相關的疾病。Intra-Cellular Therapies, Inc.成立於2002年，總部位於紐約州紐約市。

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

公司網址

https://www.intracellulartherapies.com